Climb Bio (CLYM) announced the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Before joining Climb Bio, Dr. Wilson served as ...

In a challenging market environment, shares of Eliem Therapeutics, Inc. (CLYM) have reached a 52-week low, dipping to $1.5. According to InvestingPro data, the company maintains a strong financial ...

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its ...

在充满挑战的市场环境下，Eliem Therapeutics, Inc. (CLYM)的股价已触及52周新低，跌至1.5美元。根据InvestingPro数据显示，该公司保持着稳健的财务状况，流动比率为57.7，资产负债表上现金多于债务。这家专注于开发神经系统疾病治疗方案的生物制药公司，其股价在过去一年中已从高位大幅回落。投资者目睹了公司市值的显著下降，过去六个月股价暴跌74%，目前市值为1.04 ...

Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) traded down 0.5% during trading on Wednesday .The company traded as low as $1.78 and last traded at $1.87. 260,564 shares changed hands during mid ...

Research analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Climb Bio in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.